Background: Chronic hepatitis C virus (HCV) infection is associated with autoimmune phenomena and is often complicated by anemia. Circulating autoantibodies to endogenous erythropoietin (anti-EPO) have been detected in patients with chronic viral infections and were correlated to anemia. The present study aimed to determine anti-EPO prevalence in patients with chronic HCV infection and investigate its possible association with anemia.
Methods: Ninety-three consecutive patients (62 males and 31 females) with chronic HCV infection, who had never received antiviral therapy or recombinant EPO, were enrolled in the study. Circulating anti-EPO were detected in the serum by using an ELISA assay. Quantitative determination of serum EPO levels was done by radioimmunoassay. HCV RNA viral load measurement and genotype sequencing were also performed.
Results: Circulating anti-EPO were detected in 10.8% of HCV-infected patients and the prevalence of anti-EPO was significantly higher in patients with anemia (19.4% vs 5.3%, P=0.040) compared to that in those without anemia. Compared to anti-EPO negative cases, anti-EPO positive patients had higher frequency of anemia (70.0% vs 34.9%, P=0.030), lower EPO concentrations (median 16.35 vs 30.65 mU/mL, P=0.005), and higher HCV RNA viral load (median 891.5X10 vs 367.5X10 IU/mL, P=0.016). In multivariate regression analysis the presence of anti-EPO remained an independent predictor of anemia (adjusted OR: 14.303, 95% CI: 1.417-36.580, P=0.024). EPO response to anemia was less prominent among anti-EPO positive patients (P=0.001).
Conclusions: Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1499-3872(16)60131-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study on Internal Standards Applicable to the Detection of Recombinant Erythropoietin.
Drug Test Anal
December 2024
Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China.
Article Synopsis
- The discovery of the c.577del variant in the EPO gene has complicated testing for recombinant erythropoietin (rEPO), making detection more challenging.
- Researchers developed a new confirmation method that combines reverse-normal immunopurification, western blotting (WB), and SAR-PAGE to effectively identify both the EPO variant (VAR-EPO) and rEPO using specific antibodies.
- An internal standard (IS) made from VAR-EPO modified with polyethylene glycol (PEG) was created and shown to effectively monitor rEPO detection in urine samples, ensuring reliable doping analysis results.
Introduction of a PEGylated EPO conjugate as internal standard for EPO analysis in doping controls.
Drug Test Anal
August 2024
Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
Immunopurification of doping control samples is a mandatory necessity in erythropoietin (EPO) analysis during a confirmation procedure; moreover, it has become common practice to also immunopurify samples for the initial testing procedure. Typically used materials (e.g.
View Article and Find Full Text PDFAn optimized SDS-PAGE protocol with a new blotting system for the initial testing procedure of ESAs in doping control.
Drug Test Anal
January 2022
Analysis Department, Agence Française de Lutte contre le Dopage (AFLD), Châtenay-Malabry, France.
Recombinant erythropoietins (rEPOs) are still among the substances endurance athletes use for doping. Detection methods are based on an electrophoretic separation of the proteins followed by a western blot and immunodetection with specific anti-EPO antibodies. In addition to IEF-PAGE, the SDS-PAGE method has been used to differentiate endogenous EPO from rEPOs by their molecular weight (MW).
View Article and Find Full Text PDFHorseradish-peroxidase-conjugated anti-erythropoietin antibodies for direct recombinant human erythropoietin detection: Proof of concept.
Drug Test Anal
March 2021
Anti-Doping Lab Qatar, Doha, Qatar.
Antidoping testing for recombinant human erythropoietin (EPO) is routinely performed by gel electrophoresis followed by western blot analysis with primary and secondary antibodies. The two antibody steps add more than 24 h to the testing time of a purified sample. The aim of this study was to test the concept of using directly horseradish-peroxidase (HRP)-conjugated anti-EPO primary antibody, without the need for a secondary antibody, to reduce the analysis time and eliminate non-specific cross-reactivity with secondary antibodies.
View Article and Find Full Text PDFImproved detection methods significantly increase the detection window for EPO microdoses.
Drug Test Anal
January 2021
Analysis Department - Agence Française de Lutte contre le Dopage (AFLD), Châtenay-Malabry, France.
To reproduce a potential doping scenario, a 2 week administration of recombinant erythropoietin (rEPO) microdoses alone or in combination with growth hormone (GH) microdoses (three times a week) was performed on healthy and athletic male subjects. The aim of this study was to evaluate the identification capability of rEPO in samples obtained during and post treatment. Detection was tested in urine and blood using the antidoping techniques for rEPO detection (iso-electric focusing (IEF)-, sodium-dodecyl-sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and for some urine samples the sarcosyl (SAR)-PAGE method) with some improvements: for blood samples, instead of a simple concentration step, immuno-extraction of EPO was performed for all urines to limit protein contamination that can affect migration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!